AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

63.10USD
27 Jan 2015
Change (% chg)

$0.27 (+0.43%)
Prev Close
$62.83
Open
$62.26
Day's High
$63.50
Day's Low
$62.26
Volume
1,312,026
Avg. Vol
1,804,348
52-wk High
$70.76
52-wk Low
$45.51

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a global research-based pharmaceuticals company. The Company’s products are used to treat chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn’s disease; human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease, and complications associated with... (more)

Overall

Beta: --
Market Cap(Mil.): $100,546.80
Shares Outstanding(Mil.): 1,593.45
Dividend: 0.49
Yield (%): 3.11

Financials

  ABBV.N Industry Sector
P/E (TTM): 27.35 39.77 40.41
EPS (TTM): 2.31 -- --
ROI: 17.19 19.02 18.28
ROE: 90.29 19.82 19.19
Search Stocks

PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary

- Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis, the latest Gilead victory in a market share battle with AbbVie over their new treatments for the liver destroying virus.

26 Jan 2015

PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary

Jan 26 - Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis, the latest Gilead victory in a market share battle with AbbVie over their new treatments for the liver destroying virus.

26 Jan 2015

Express Scripts' Miller says hepatitis C price war to save billions

NEW YORK - Gilead Sciences Inc and AbbVie Inc are in a price war over their hepatitis C treatments that is driving costs lower and has changed the way drugmakers price new medicines, a top executive for pharmacy benefit manager Express Scripts said on Thursday.

22 Jan 2015

Gilead, AbbVie hit by fresh concerns on Hep C discounting

- Shares of Gilead Sciences Inc closed down 6 percent on Tuesday, after a pharmacy benefit manager said it would cover both Gilead and rival AbbVie Inc's hepatitis C offering, renewing concerns of pricing pressure.

13 Jan 2015

Exclusive: Hedge fund Mason Capital ends 2014 down 12 percent - source

BOSTON - Hedge fund Mason Capital lost 12 percent in 2014, making for one of the industry's biggest declines, after the New York-based firm was hit by a failed merger of pharmaceuticals companies Shire and AbbVie, a person familiar with the firm said in Monday.

12 Jan 2015

AbbVie wins U.S. approval for Parkinson's treatment

- The U.S. Food and Drug Administration approved AbbVie Inc's treatment for Parkinson's disease.

12 Jan 2015

CORRECTED-UPDATE 1-AbbVie wins U.S. approval for Parkinson's treatment

Jan 12 - The U.S. Food and Drug Administration approved AbbVie Inc's treatment for Parkinson's disease.

12 Jan 2015

CORRECTED-AbbVie wins U.S. approval for Parkinson's treatment

Jan 12 - The U.S. Food and Drug Administration approved AbbVie Inc's treatment for Parkinson's disease.

12 Jan 2015

Breakingviews: Shire gambles AbbVie break fee on risky $5 bln deal

LONDON (Reuters Breakingviews) - Shire is gambling its AbbVie break fee on risky M&A. The Dublin-based pharma group has agreed to buy U.S. peer NPS to expand in lucrative rare drugs. The 51 percent premium is covered almost entirely by compensation from the collapse of Shire's sale to larger American rival AbbVie last year. That doesn't much mitigate the risk of doing a deal ahead of a key regulatory ruling.

12 Jan 2015

US STOCKS-Futures dip after two-day run, ahead of payrolls

* Futures off: Dow 61 pts, S&P 7.25 pts, Nasdaq 8.5 pts (Adds premarket actives)

09 Jan 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $102.09 -0.17
Pfizer Inc. (PFE.N) $32.60 -0.20
Novartis AG (NOVN.VX) CHF88.80 -0.05
Merck & Co., Inc. (MRK.N) $62.56 -0.26
Roche Holding Ltd. (ROG.VX) CHF253.10 -4.20
Abbott Laboratories (ABT.N) $43.68 -0.47
Eli Lilly and Co (LLY.N) $71.73 -0.38

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks